Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 179
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Quarterly Psychedelics Briefing: Q3 2026
Weekly Psychedelic Policy Briefing, September 21, 2026
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Pα+ Psychedelic Bulletin #232: Q2’26 Psychedelic Lobbying Update; DEA Again Moves to Schedule 5 Tryptamines; Oregon Backpedals Psilocybin Fee Hike
Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers
Opening the Mushroom Pharmacopeia: The Case of Norbaeocystin
PT343 – Soren Shade – Kratom and Anti-Prohibition: Lessons Learned and...
COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord...
Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
atai Life Sciences to Announce Second Quarter 2022 Financial Results and...
BREAKING: Morgan Stanley Publishes Optimistic Report on Psychedelics
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study...
FILAMENT HEALTH ANNOUNCES PARTICIPATION IN PROJECT SOLACE
PT342 – Spencer Hawkswell – The Right to Psilocybin in Canada:...
Psychedelic Bulletin #112 – Inside the DEA Challenge; Second Psychedelics Company...
Load more